SCHEMBL359439

SCHEMBL359439

COC(=O)c1ccc(C=O)cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.63
HPGD P15428 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
MAPT P10636 2/20 0.63
CYP2C9 P11712 2/20 0.63
CYP1A2 P05177 1/20 0.63
HSP90AA1 P07900 1/20 0.63
CYP2C19 P33261 1/20 0.63
TSHR P16473 1/20 0.59
TRIM24 O15164 1/20 0.59
ALDH5A1 P51649 1/20 0.59
ABAT P80404 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
TRIM33 Q9UPN9 1/20 0.59
AOX1 Q06278 1/20 0.54
FDPS P14324 1/20 0.51
KDM4E B2RXH2 1/20 0.51
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
TTR P02766 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30362132 0.88 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL1505421 0.88 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL16961313 0.86 ALDH1A1 (0.49) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL14321618 0.85 TRPA1 (0.57) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL7033712 0.84 ALDH1A1 (0.61) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL3909451 0.84 CYP2C9 (0.62) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL19699322 0.84 ALDH1A1 (0.53) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL5033639 0.84 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL11469172 0.84 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9
SCHEMBL25214183 0.83 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741386-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-13 EP disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 US disclosed
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 2025-03-06 US disclosed
EP-4516779-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-03-05 EP disclosed
WO-2025007777-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-09 WO disclosed
CN-118666618-A Synthesis method of aromatic aldehyde iodo compound 阜阳师范大学 2024-09-20 CN disclosed
CN-118660872-A Pyrimidine compound, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2024-09-17 CN disclosed
WO-2024146541-A1 MACROCYCLIC COMPOUNDS AS USP1 INHIBITORS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2024-07-11 WO disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
WO-2024148274-A1 COMPLEMENT INHIBITION APELLIS PHARMACEUTICALS, INC. (US) 2024-07-11 WO disclosed
EP-0831891-A1 OXIDANT SCAVENGERS DUKE UNIVERSITY (US) 1998-04-01 EP disclosed
WO-1996040223-A1 OXIDANT SCAVENGERS DUKE UNIVERSITY (US) 1996-12-19 WO disclosed
EP-0394440-B1 PHENYLCARBOXYLIC ACID DERIVATIVES OTSUKA PHARMA CO LTD (JP) 1994-05-11 EP disclosed
US-4999378-A Antilipemic, anticholesterol, antidiabetic, treatment of atherosclerosis and obesity OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1991-03-12 US disclosed
EP-0394440-A1 PHENYLCARBOXYLIC ACID DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-10-31 EP disclosed
US-4753962-A HYPOGLYCEMIC, ANTIOBESITY AGENT BEECHAM GROUP P.L.C. (GB) 1988-06-28 US disclosed
US-4654371-A ANTI-OBESITY, HYPOGLYCEMIA AGENTS BEECHAM GROUP P.L.C. (GB) 1987-03-31 US disclosed
US-4478849-A HYPERGLYCEMIC AGENTS BEECHAM GROUP LIMITED (GB) 1984-10-23 US disclosed
EP-0006735-B1 SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE BEECHAM GROUP PLC (GB) 1983-06-15 EP disclosed
EP-0006735-A1 Secondary amines, their preparation, pharmaceutical compositions containing them and their use BEECHAM GROUP PLC (GB) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074904-A1 NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF NCOR2, NSD2, NCOR1 ALDH1A1 4559/4885HPGD 2600/4885SMN1; SMN2 2048/4885
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF USP1, UPP1, UFL1 ALDH1A1 336/4885HPGD 1921/4885SMN1; SMN2 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.